Global timing of hepatitis C virus elimination in high-income countries.
Homie Razavi, Yuri Sanchez Gonzalez, Cammy Yuen...
https://pubmed.ncbi.nlm.nih.gov/31815353Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID05361603
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-Conventional Facilities Using Rapid Diagnostic Tests and FibroScan
Led by University Hospital, Limoges · Updated on 2022-05-04
1500
Participants Needed
1
Research Sites
374 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the acceptability of simultaneous screening for viral Hepatitis B, Hepatitis C, and HIV among drug users in non-conventional care settings. The study involves coordinated monthly screening days where health professionals including hepatologists, addictologists, nurses, and social workers work together to assess and provide appropriate management for each participant. This approach is designed to offer comprehensive screening and care in a supportive environment outside traditional healthcare facilities. The screening process includes several steps: patients visiting on screening days receive individualized attention and data collection by the care team. They are offered rapid diagnostic tests (TRODs) for Hepatitis B, C, and HIV, and a FibroScan to assess liver health. Positive results lead to additional tests like delocalized PCR for Hepatitis C RNA or blood tests for HIV and Hepatitis B serologies. Immediate consultation with a hepatologist follows, with confidential result delivery and discussion of further care options. Prevention advice and vaccination for Hepatitis B may also be provided. Participants engage in routine care procedures, including diagnostic tests and consultations during the screening days. Researchers monitor the number of tests performed, patient attendance, acceptance of consultations, vaccination rates, treatment initiations, and treatment adherence over a period of up to 10 years. This long-term follow-up helps assess the program's impact on managing viral infections among drug users, with ongoing support provided by the healthcare team throughout the study duration.
CONDITIONS
Brief Title
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adult 18 and over
- Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
- Patient who agreed to participate to the research
You will not qualify if you...
- Patient doesn't agree to participate to the research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Same day
Participants undergo simultaneous rapid diagnostic tests for viral Hepatitis B, C, and HIV along with a FibroScan to assess liver condition. Positive tests may lead to immediate additional blood tests or PCR testing and consultation with a hepatologist.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 10 years
Participants who test positive may start treatment immediately and have follow-up appointments, including a control test approximately 3 months after treatment to confirm cure. Prevention and vaccination may also be offered during this period.
Follow-up visits as scheduled, including a control visit at 3 months post-treatment
Trial Site Locations
Total: 1 location
1
Chu Limoges
Limoges, Haute Vienne, France, 87042
Actively Recruiting
Loading map...
Research Team
M
Marilyne DEBETTE-GRATIEN, MD
V
Véronique LOUSTAUD-RATTI, Prof
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Albert Tran, Sarah Shili-Masmoudi, Lucile Moga...
https://pubmed.ncbi.nlm.nih.gov/34332129The remarkable history of the hepatitis C virus.
Stanislas Pol, Sylvie Lagaye
https://pubmed.ncbi.nlm.nih.gov/31019253French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long.
Cécile Brouard, Josiane Pillonel, Marjorie Boussac...
https://pubmed.ncbi.nlm.nih.gov/33059617HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy.
Cécile Brouard, Leïla Saboni, Arnaud Gautier...
https://pubmed.ncbi.nlm.nih.gov/31660879Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Sahar Bajis, Jason Grebely, Behzad Hajarizadeh...
https://pubmed.ncbi.nlm.nih.gov/31698545Strategies for the improvement of HCV testing and diagnosis.
Stéphane Chevaliez
https://pubmed.ncbi.nlm.nih.gov/30950298Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA.
David Smookler, Aaron Vanderhoff, Mia J Biondi...
https://pubmed.ncbi.nlm.nih.gov/32763480Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.
Marilyne Debette-Gratien, Sandrine François, Catherine Chevalier...
https://pubmed.ncbi.nlm.nih.gov/36597183